Evidence map›Paper›PMID 42884043›Full record

ArticleInternational journal of molecular sciences2026

Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis.

Alena I Zagrebneva, Elena N Simonova, Yuliya A Gavrikova, Vladislav V Dolgov, Anastasiia A Buianova, Ekaterina D Glumova, Maria I Tubalova, Galina S Koksharova, Artem R Nurislamov, Vadim I Mazurov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alena I ZagrebnevaOrganizational and Methodological Department, North-Western State Medical University Named After I.I. Mechnikov, 41, Kirochnaya St., Saint Petersburg 191015, Russia.ORCID 0000-0002-3235-1425
Elena N SimonovaMoscow Clinical Research Center "Hospital No. 52", 3, Pekhotnaya St., Moscow 123182, Russia.
Yuliya A GavrikovaMoscow Clinical Research Center "Hospital No. 52", 3, Pekhotnaya St., Moscow 123182, Russia.ORCID 0000-0001-8414-1545
Vladislav V DolgovMoscow Clinical Research Center "Hospital No. 52", 3, Pekhotnaya St., Moscow 123182, Russia.ORCID 0000-0001-8007-5499
Anastasiia A BuianovaMoscow Clinical Research Center "Hospital No. 52", 3, Pekhotnaya St., Moscow 123182, Russia.ORCID 0000-0001-7894-9222
Ekaterina D GlumovaInstitute of Cytology and Genetics, Russian Academy of Sciences, Novosibirsk 630090, Russia.
Maria I TubalovaInstitute of Cytology and Genetics, Russian Academy of Sciences, Novosibirsk 630090, Russia.ORCID 0009-0000-1894-9458
Galina S KoksharovaInstitute of Cytology and Genetics, Russian Academy of Sciences, Novosibirsk 630090, Russia.ORCID 0000-0001-5664-492X
Artem R NurislamovInstitute of Cytology and Genetics, Russian Academy of Sciences, Novosibirsk 630090, Russia.ORCID 0000-0002-0553-1316
Vadim I MazurovOrganizational and Methodological Department, North-Western State Medical University Named After I.I. Mechnikov, 41, Kirochnaya St., Saint Petersburg 191015, Russia.

Funding

Ministry of Health of the Russian Federation 1025101700003-6
6 · The paper itself

Abstract

Genetic determinants of response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) remain insufficiently characterized. We developed a targeted sequencing panel of candidate immunogenetic variants identified through a literature review and evaluated associations with response to TNF-α inhibitors, response to IL-6 inhibitors, and difficult-to-treat RA (D2TRA). Whole-blood DNA was sequenced using custom hybridization capture on a DNBSEQ-G400 platform (2 × 150 bp). Reads were aligned to hg38 using BWA-MEM, and variants were called with GATK HaplotypeCaller. After quality control, the D2TRA analysis included 154 patients (59 D2TRA and 95 non-D2TRA); drug-response analyses included 66 anti-TNF patients (26 responders, 40 non-responders) and 69 anti-IL-6 patients (29 responders, 40 non-responders). Treatment-response associations were assessed using unadjusted allelic chi-square tests with multiple-testing correction; D2TRA was analyzed using logistic regression adjusted for age, sex, and body mass index. For IL-6 inhibitor response, rs11656130/

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAgedFemaleHumansInterleukin-6MaleMiddle AgedPolymorphism, Single NucleotideTreatment Effect HeterogeneityTreatment OutcomeTumor Necrosis Factor-alphaAntirheumatic AgentsInterleukin-6Tumor Necrosis Factor-alphabiologic DMARDscandidate-variant analysisdifficult-to-treat RAIL-6 inhibitorspharmacogeneticsrheumatoid arthritistargeted sequencingTNF-α inhibitors

Identifiers

PMID42884043
PMCPMC13664733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.